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Purpose. The objective of this study was to compare the salivary protein proﬁles from individuals diagnosed with breast cancer
that were either HER2/neu receptor positive or negative. Methods. Two pooled saliva specimens underwent proteomic analysis.
One pooled specimen was from women diagnosed with stage IIa HER2/neu-receptor-positive breast cancer patients (n = 10) and
the other was from women diagnosed with stage IIa HER2/neu-receptor-negative cancer patients (n = 10). The pooled samples
were trypsinized and the peptides labeled with iTRAQ reagent. Specimens were analyzed using an LC-MS/MS mass spectrometer.
Results. The results yielded approximately 71 diﬀerentially expressed proteins in the saliva specimens. There were 34 upregulated
proteins and 37 downregulated proteins.
1.Introduction
Clinicopathologic factors such as histological type, tumor
size, tumor grade, hormone receptor status, lymph node
involvement, and HER-2/neu overexpression are recognized
as having prognostic use in breast cancer management.
HER-2/neu (HER2), also known as c-erbB-2, is a biomarker
assayed in tissue biopsies from women diagnosed with
malignant breast tumors [1, 2]. Used primarily as a prog-
nostic indicator, HER2/neu protein is overexpressed in
approximately 20%–30% of malignant breast tumors and
has been used in postoperative followup evaluation as an
indicator of patient relapse [3–6].
The evolution of HER2 testing, ﬁrst as a prognostic
marker assay and later as a diagnostic test to determine
eligibility for trastuzumab-targeted therapy, has expanded
the role of traditional diagnostic pathology. Unlike most
testing performed by anatomic pathologists, which serves as
an adjunct to establishing a diagnosis, the results of HER2
testingstandaloneindeterminingwhichpatientsarelikelyto
respond to trastuzumab therapy. HER2 status may also pre-
dict sensitivity to certain cytotoxic drugs and antiestrogens
[3–6].
Currently, two testing methods are approved by the
Food and Drug Administration (FDA) for HER2 assessment
in the laboratory [1, 2]. They are immunohistochemical
analysis (IHC) and ﬂuorescence in situhybridization (FISH).
Commercially available, FDA-approved HER2 assays are
available for both methods. Immunohistochemical analysis
and FISH have the advantage over other assay methods
(i.e., those requiring homogenization) because they are
morphologically driven. This allows for the direct evaluation
of tumor cells, correlation with other morphologic features,
andtheabilitytoassaysmallerpatientsamplessuchasneedle
core biopsy specimens [1, 2].
While clinical treatment choices are critical, the actual
tests used to determine HER2 status have demonstrated a
number of pitfalls. One such pitfall is the number of false
negatives and false positives associated with the tests. This
creates a treatment dilemma as it can result in situations2 Journal of Oncology
where patients requiring trastuzumab-targeted therapy may
not receive it, while those receiving trastuzumab-targeted
therapy should not receive it [6–8].
Not everyone is convinced that the problem is as simple
as false negatives and false positives. One problem may
be with the cutoﬀ points that scientists have established
to delineate between HER2 negative and positive in IHC
testing. Data from several preclinical and clinical studies
suggest that trastuzumab activity does not strictly require
HER2 overexpression or gene ampliﬁcation, as is currently
thought. Instead, even tumor cells that express a lower
level of the protein might respond to a trastuzumab-
chemotherapy combination. Currently, tumors that have
moderate amounts of HER2 protein would be scored as 1+
or2+onIHCtestsandwouldbecallednegativebecausethey
are below the predetermined cutoﬀ value for the test [1–8].
Even FISH testing, which is considered the “gold stan-
dard” for detecting gene ampliﬁcation, has problems. The
test measures the ratio between the area surrounding the
HER2 gene on chromosome 17 and other parts of chro-
mosome 17. That means a cell that has extra copies of
chromosome 17, called polysomy 17, appears negative by
F I S Hb u ta c t u a l l yh a se x t r ac o p i e so fH E R 2 ,a n dp r o b a b l y
expresses more protein than a wild-type cell would [1, 2].
The inconsistency in the test may stem, in part, from
heterogeneity of HER2 expression in the tumor sample. If so,
then multiple tests on the same tumor could yield diﬀerent
results, even though the tests are working as designed. The
testing problem has been a matter of discussion, and how
it will be resolved remains unclear. However, clinicians and
researchers agree that current technology to assess HER2
status needs improvement [1–8].
Therefore, the purpose of this study was twofold. The
ﬁrstobjectivewastocomparesalivaryproteinproﬁlesamong
Her2-receptor-positive and -negative breast cancer patients
and secondly, to support the theory for using salivary protein
proﬁle expression as a method for modeling breast cancer
progression [9, 10].
2. Methods
2.1. Design. The investigators protein proﬁled three pooled,
stimulated whole saliva specimens. One specimen consisted
of pooled saliva from 10 stage IIa (T2N0M0)H E R 2 - r e c e p t o r -
status-positiveinvasiveductalcarcinomapatients(IDC),and
the second pooled specimen was from 10 subjects diagnosed
with stage IIb (T2N0M0), HER2-receptor-status-positive
invasiveductalcarcinoma.Thecancercohortswereestrogen,
progesterone receptor status negative as determined by the
pathology report. Histological grade was not available for
this study. The subjects were matched for age and race and
were nontobacco users.
The participating subjects were given an explanation
about their participation rights, and they signed an IRB
consent form. The saliva specimens and related patient
data are nonlinked and bar-coded in order to protect
patient conﬁdentiality. This study was performed under the
UTHSC IRB-approved protocol number HSC-DB-05-0394.
All procedures were in accordance with the ethical standards
of the UTHSC IRB and with the Helsinki Declaration of
1975, as revised in 1983.
2.2. Saliva Collection and Sample Preparation. Stimulated
whole salivary gland secretion is based on the reﬂex response
occurring during the mastication of a bolus of food.
Usually, a standardized bolus (1 gram) of paraﬃno ra
gum base (generously provided by the Wrigley Co., Peoria,
IL) is given to the subject to chew at a regular rate. The
individual, upon suﬃcient accumulation of saliva in the oral
cavity,expectoratesperiodicallyintoapreweigheddisposable
plastic cup. This procedure is continued for a period of
ﬁve minutes. The volume and ﬂow rate is then recorded
along with a brief description of the specimen’s physical
appearance [9, 10]. The cup with the saliva specimen is
reweighed and the ﬂow rate determined gravimetrically. A
protease inhibitor from Sigma Co. (St. Louis, MI, USA) is
added along with enough orthovanadate from a 100mM
stock solution to bring its concentration to 1mM. The
treated samples were centrifuged for 10 minutes at top speed
in a tabletop centrifuge. The supernatant was divided into
1mLaliquotsandfrozenat−80.
2.3. Two-Dimensional Gel Analysis (2D DIGE)
2.3.1. Sample Preparation. 2D DIGE and protein ID was
performed by Applied Biomics, Inc. (Hayward, CA). Pro-
teins from the saliva were precipitated by methanol then
resuspended in a 2D cell lysis buﬀer (30mM Tris-HCl, pH
8.8, containing 7M urea, 2M thiourea, and 4% CHAPS).
Protein concentration was measured using Bio-Rad protein
assay method.
2.3.2. CyDye Labeling. For each sample, 30ug of protein was
mixed with 1.0µL of diluted CyDye and kept in dark on
ice for 30min. Samples from each pair were labeled with
Cy2 and Cy5, respectively. The labeling reaction was stopped
by adding 1.0µL of 10mM Lysine to each sample, and
incubating in dark on ice for additional 15min. The labeled
samples were then mixed together. The 2X 2D sample buﬀer
(8M urea, 4% CHAPS, 20mg/mL DTT, 2% pharmalytes,
and trace amount of bromophenol blue), 100µL destreak
solution, and Rehydration buﬀer (7M urea, 2M thiourea,
4% CHAPS, 20mg/mL DTT, 1% pharmalytes, and trace
amount of bromophenol blue) were added to the labeling
mix to make the total volume of 250µL. They were Mixed
well and spined before loading the labeled samples into strip
holder.
2.3.3. IEF and SDS-PAGE. After loading the labeled samples,
IEF (pH3-10 Linear) was run following the protocol pro-
vided by Amersham BioSciences. Upon ﬁnishing the IEF, the
IPG strips were incubated in the freshly made equilibration
buﬀer 1 (50mM Tris-HCl, pH 8.8, containing 6M urea,
30% glycerol, 2% SDS, trace amount of bromophenol blue,
and 10mg/mL DTT) for 15 minutes with gentle shaking.
Then the strips were rinsed in the freshly made equilibrationJournal of Oncology 3
Table 1: Upregulated salivary proteins.
Access no. Gene ID %Cov Name Ratio P value
P63261 ACTG 65.1 Actin, cytoplasmic 2 1.207 0.030
P07108 ACBP 28.7 Acyl-CoA-binding protein 1.161 0.002
P06733 ENOA 61.3 Alpha-enolase 1.193 0.030
P04083 ANXA1 56.1 Annexin A1 1.457 0.000
P03973 ALK1 36.4 Antileukoproteinase 1 precursor 2.188 0.004
Q8N4F0 BPIL1 27.3 Bactericidal/permeabilityincreasing 1.386 0.000
P35321 SPR1A 70.8 Corniﬁn-A 1.696 0.003
P22528 SPR1B 61.8 Corniﬁn-B 1.722 0.000
P01040 CYTA 87.8 Cystatin-A 1.788 0.000
P04080 CYTB 72.4 Cystatin-B 1.514 0.000
P01034 CYTC 62.3 Cystatin-C precursor 1.183 0.030
P35527 K1C9 25.5 Cytokeratin-9 1.512 0.001
Q9UGM3 DMBT1 39.0 Deleted in malignant brain tumors 1 1.191 0.000
Q01469 FABPE 45.2 Fatty acid-binding protein, epidermal 1.191 0.000
P01877 IGHA2 52.6 Ig alpha-2 chain C region 1.125 0.040
P01834 KAC 88.7 Ig kappa chain C region 1.128 0.040
P06309 KV205 31.6 Ig kappa chain V-II region GM607 1.274 0.030
P18510 IL1RA 31.6 Interleukin-1 receptor antagonist protein 2.050 0.000
P22079 PERL 46.5 Lactoperoxidase precursor 1.190 0.000
P31025 LCN1 46.6 Lipocalin-1 precursor 1.853 0.000
P26038 MOES 15.3 Moesin 1.991 0.020
P62937 PPIA 58.2 Peptidyl-prolyl cis-trans-isomerase A 1.553 0.003
P01833 PIGR 58.4 Polymeric-immunoglobulin receptor 1.452 0.000
Q16378 PROL4 58.2 Proline-rich protein 4 precursor 3.092 0.000
P05109 S10A8 58.1 Protein S100-A8 1.318 0.000
P06702 S10A9 57.0 Protein S100-A9 1.833 0.000
Q96DA0 U773 27.5 Protein UNQ773/PRO1567 precursor 1.930 0.000
P29508 SPB3 20.3 Serpin B3 2.910 0.000
Q96DR5 SPLC2 52.2 Short-palate lung and nasal epith. carc. 1.435 0.000
Q9UBC9 SPRR3 81.1 Small proline-rich protein 3 2.035 0.000
P60174 TPIS 42.2 Triosephosphate isomerase 1.257 0.012
P07477 TRY1 35.2 Trypsin-1 precursor 3.135 0.000
P62988 UBIQ 68.4 Ubiquitin 1.142 0.003
Q6P5S2 CF058 31.8 Uncharacterized protein C6orf58 1.603 0.000
buﬀer 2 (50mM Tris-HCl, pH 8.8, containing 6M urea, 30%
glycerol, 2% SDS, trace amount of bromophenol blue, and
45mg/mL DTT) for 10 minutes with gentle shaking. Next,
the IPG strips were rinsed in the SDS-gel running buﬀer
before transferring into 13.5% SDS gels. The SDS gels were
run at 15◦C until the dye front exuded out of the gels.
2.3.4. Image Scan and Data Analysis. Gel images were
scanned immediately following the SDS-PAGE using Ty-
phoon TRIO (Amersham BioSciences). The scanned images
were then analyzed by Image Quant software (version
6.0, Amersham BioSciences), followed by in-gel analy-
sis using DeCyder software version 6.0 (Amersham Bi-
oSciences). The fold change of the protein expression levels
was obtained from in-gel DeCyder analysis.
2.4. Top-Down Mass Spectrometry Using iTRAQ Labeling. A
thorough explanation for the top-down mass spectrometry
using iTRAQ labeling can be found in detail in previ-
o u sp u b l i c a t i o n s[ 9, 10]. Brieﬂy, the saliva samples were
thawed and immediately centrifuged to remove insoluble
materials. The supernatant was assayed for protein using
the Bio-Rad protein assay (Hercules, CA, USA), and an
aliquot containing 100µg of each specimen was precipitated
with six volumes of −20◦C acetone. The precipitate was
resuspended and treated according to the manufacturer’s
instructions. Protein digestion and reaction with iTRAQ
labels was carried out as previously described and according
to the manufacturer’s instructions (Applied Biosystems,
Foster City, CA). Brieﬂy, the acetone precipitable protein
was centrifuged in a tabletop centrifuge at 15,000×gf o r4 Journal of Oncology
Table 2: Downregulated salivary proteins.
Access no. Gene ID %Cov Name Ratio P value
Q01518 CAP1 11.4 Adenylyl cyclase 0.7295 0.0077
P02763 |A1AG1 37.8 Alpha-1-acid glycoprotein 0.7571 0.0070
P04217 A1BG 21.2 Alpha-1B-glycoprotein 0.5602 0.0420
P01023 A2MG 23.3 Alpha-2-macroglobulin 0.4395 0.0000
P02647 APOA1 52.1 Apolipoprotein A-I 0.8928 0.0488
P02812 PRB2 100.0 Salivary prp 2 0.8307 0.0020
P01024 CO3 18.3 Complement C3 0.7227 0.0434
P28325 CYTD 39.4 Cystatin-D 0.8297 0.0027
P09228 CYTT 76.6 Cystatin-SA 0.7736 0.0003
P13646 K1C13 70.3 cytoskeletal 13 0.1058 0.0000
P19013 K2C4 72.3 cytoskeletal 4 0.1269 0.0000
P13647 K2C5 53.7 cytoskeletal 5 0.2291 0.0019
P06396 GELS 34.7 Gelsolin 0.6744 0.0004
P00738 HPT 51.2 Haptoglobin 0.6346 0.0000
P69905 HBA 31.7 Hemoglobin subunit alpha 0.5039 0.0000
P68871 HBB 56.5 Hemoglobin subunit beta 0.6774 0.0000
P16403 H12 18.8 Histone H1.2 0.3436 0.0056
P16104 H2AX 34.3 Histone H2A.x (H2a/x) 0.1531 0.0014
Q16778 |H2B2E 38.1 Histone H2B type 2-E 0.2383 0.0005
Q71DI3 H32 39.0 Histone H3.2 0.1580 0.0000
P62805 H4 50.5 Histone H4 0.1913 0.0000
P01857 IGHG1 46.4 Ig gamma-1 chain C region 0.5308 0.0000
P01859 IGHG2 42.0 Ig gamma-2 chain C region 0.5593 0.0000
P01777 HV316 20.2 Ig heavy chain V-III region TEI 0.6363 0.0408
P01842 LAC 83.8 Ig lambda chain C regions 0.7805 0.0017
P01871 MUC 30.2 Ig mu chain C region 0.7708 0.0009
P02788 TRFL 58.5 Lactotransferrin 0.8219 0.0012
P08246 ELNE 9.7 Leukocyte elastase 0.5594 0.0304
P14780 MMP9 28.0 Matrix metalloproteinase-9 0.5891 0.0002
P05164 PERM 37.0 Myeloperoxidase 0.4892 0.0016
P80303 NUCB2 27.1 Nucleobindin-2 0.8093 0.0370
Q06830 PRDX1 15.1 Peroxiredoxin-1 0.7488 0.0010
P07737 PROF1 65.7 Proﬁlin-1 0.6752 0.0010
P80511 S10AC 40.2 Protein S100-A12 0.7363 0.0121
Q08188 TGM3 20.8 Glutamyltransferase E precursor 0.6357 0.0074
P02787 TRFE 51.6 Serotransferrin precursor 0.5730 0.0000
P37837 TALDO 29.7 Transaldolase 0.6777 0.0119
P08670 VIME 27.5 Vimentin 0.4832 0.0407
20 minutes. The acetone supernatant was removed and
the pellet resuspended in 20U ¸ L dissolution buﬀer. The
soluble fraction was denatured, and disulﬁdes were reduced
by incubation in the presence of 0.1% SDS and 5mM
TCEP (tris-(2-carboxyethyl) phosphine) at 60◦C for one
hour. Cysteine residues were blocked by incubation at room
temperature for 10 minutes with MMTS (methyl methane-
thiosulfonate). Trypsin was added to the mixture to a
protein: trypsin ratio of 10:1. The mixture was incubated
overnightat37◦C.Theproteindigestswerelabeledbymixing
with the appropriate iTRAQ reagent and incubating at room
temperature for one hour. On completion of the labeling
reaction, the four separate iTRAQ reaction mixtures were
combined. Since there are a number of components that can
interfere with the LCMSMS analysis, the labeled peptides are
partiallypuriﬁedbyacombinationofstrongcationexchange
followed by reverse-phase chromatography on preparative
columns. The combined peptide mixture is diluted 10-fold
with loading buﬀer (10mM, KH2PO4 in 25% acetonitrile
at pH 3.0) and applied by syringe to an ICAT Cartridge-
Cation Exchange column (Applied Biosystems, Foster City,
CA) column that has been equilibrated with the same
buﬀer. The column is washed with 1mL loading buﬀer to
remove contaminants. To improve the resolution of peptidesJournal of Oncology 5
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Figure 1: This ﬁgure illustrates the protein proﬁles for HER2/neu-receptor-positive and HER2/neu-receptor-negative samples. As shown in
the far right red and green dyed gel comparisons, there are numerous diﬀerences between the two proﬁles.
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Figure 2:ThisﬁguredemonstratesthediﬀerencesinsalivaryproteinproﬁlesbetweenHER2/neu-positiveandHER2/neu-negativesamples.
Please change.
during LCMSMS analysis, the peptide mixture is partially
puriﬁedbyelution fromthecationexchangecolumninthree
fractions. Stepwise elution from the column is achieved with
sequential 0.5mL aliquots of 10mM KH2PO4 at pH 3.0 in
25% acetonitrile containing 116mM, 233mM, and 350mM
KCl, respectively. The fractions are evaporated by Speed Vac
to about 30% of their volume to remove the acetonitrile and
thenslowlyappliedtoanOpti-LynxTrapC18100µLreverse-
phase column (Alltech, Deerﬁeld, IL) with a syringe. The
column was washed with 1mL of 2% acetonitrile in 0.1%
f o r m i ca c i da n de l u t e di no n ef r a c t i o nw i t h0 . 3m Lo f3 0 %
acetonitrile in 0.1% formic acid. The fractions were dried by
lyophilization and resuspended in 10µL0 . 1 %f o r m i ca c i d
in 20% acetonitrile solution. Each of the three fractions6 Journal of Oncology
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Figure 3: The ﬁgure represents the natural logarithm diﬀerential expression of salivary proteins. To the right and left of the ﬁgure listed in
rank order of expression are the up- and downregulated proteins, respectively.
was analyzed by reverse-phase nano-LCMS/MS on an API
QSTAR XL mass spectrometer (ABS Sciex Instruments).
2.5. Bioinformatics. The Swiss-Prot database was employed
for protein identiﬁcation, while the PathwayStudio bioin-
formatics software package was used to determine Venn
diagrams that were also constructed using the NIH software
program (http://ncrr.pnl.gov/). Graphic comparisons with
log conversions and error bars for protein expression were
produced using the ProQuant software. Candidates with
either protein score C.I. percentage or Ion C.I. percentage
greater than 95 were considered signiﬁcant.
3. Results
3.1.2DGelResults. Figures1and2illustratetheresultsofthe
2D gel analyses. Figure 1 demonstrates the protein compar-
isons between the pooled HER2/neu-receptor-positive and
the HER2/neu-receptor-negative pooled specimens. Figure 2
represents the spots of interest that were selected up by
Ettan Spot Picker (Amersham BioSciences) based on the in-
gel analysis and spot picking design by DeCyder software.
As shown, there are 96 spots of interest illustrated on
the 2D gel analysis. This visually indicates the diﬀering
salivary protein patterns between HER2/neu-positive and
HER2/neu-negative patients.
3.2. LC-MS/MS Mass Spectrometry Results. The results
yielded 188 comparative salivary proteins among the
HER2/neu-positive and HER2/neu-negative samples.
Among the total number of proteins, 71 were signiﬁcantly
diﬀerentially expressed between the two specimens. There
were34upregulatedproteinsand37downregulatedproteins.
Listed in Table 1 is the 34 upregulated proteins, and in
Table 2, the 37 downregulated proteins.
Of the 34 proteins listed in Table 1, the mean percent
peptide coverage for the complete panel of proteins was
50.3% (±19.6) with a range of 15.3% to 88.7% coverage.
Themeanproteinratiowas1.64 (±54.2)andrangedinvalue
with a maximum of 3.13 to a maximum minimum of 1.12.
Likewise, the mean alpha level was P<0.007(±0.013) and
ranged in value with a maximum of P<0.04 to a maximum
minimum of P<0.000001.
Of the 37 downregulated salivary proteins listed in
Table 2, the mean percent peptide coverage for the complete
panel of proteins was 40.1% (±20.7) with a range of
9.7% to 100% coverage. The mean protein ratio was 1.64
(±0.561) and ranged in value with a maximum of 0.89 to
a maximum minimum of 0.10. Likewise, the mean alpha
level was P<0.009 (±0.015) and ranged in value with
am a x i m u mo fP<0.05 to a maximum minimum of
P<0.000001. Figure 3 illustrates the comparison of the log
ratio of the relative intensity (HER2+/HER2−) of the total
71 up- and downregulated salivary proteins. Additionally,Journal of Oncology 7
Table 3: Altered protein in saliva and in SKBR3 cell lines.
Access
no. Gene ID Name Reference
P06733 ENOA Alpha-enolase [11]
P04083 ANXA1 Annexin A1 [12]
P01034 CYTC Cystatin-C precursor [12]
P35527 K1C9 Cytokeratin-9 [13]
Q01469 FABPE Fatty acid-binding protein,
epidermal
[12]
P26038 MOES Moesin [14]
P62937 PPIA Peptidyl-prolyl
cis-trans-isomerase A
[12]
P01833 PIGR Polymeric-immunoglobulin
receptor
[12]
P05109 S10A8 Protein S100-A8 [12]
P06702 S10A9 Protein S100-A9 [12]
P13646 K1C13 cytoskeletal 13 [13]
P13647 K2C5 cytoskeletal 5 [13]
P06396 GELS Gelsolin [12]
P00738 HPT Haptoglobin [12]
P16104 H2AX Histone H2A.x (H2a/x) [13]
Q16778 H2B2E Histone H2B type 2-E [13]
Q06830 PRDX1 Peroxiredoxin-1 [12]
P07737 PROF1 Proﬁlin-1 [11]
P05109 S10A8 Protein S100-A8 [12]
P06702 S10A9 Protein S100-A9 [12]
Figure 4 illustrates the protein function of the panel of
71 proteins. Proteins related to cellular metabolism and
immune response comprised nearly 42% of the protein
panel. Cellular structure constituted 17% of the protein
panel, which is consistent with SKBR3 and other cell line
protein analyses [15]. Additionally, there were a considerable
number of histones that were present in the functional
protein proﬁle.
4. Discussion
To the best of our knowledge, this is the ﬁrst attempt
to determine salivary protein proﬁle alterations related to
HER2/neu receptor status. Therefore, we have only a few
references by which to compare our data. Additionally, a
complete proteomic catalog of the SKBR3 cell line is also not
available to compare to the salivary protein proﬁles, which
are altered secondary to HER2 receptor status. Of the articles
that were identiﬁed through the PubMed Central (United
States National Library of Medicine) search engine [11–17],
twenty (28%) of the 71 of the salivary proteins were found
cited among the manuscripts [11–17]a n dr e p o r t e dt ob e
altered in the SKBR3 cell lines. These salivary proteins are
listed in Table 3 with the references that cited the SKBR3
protein phenotype alterations.
The numerous proteins in the panel need validation;
however, the authors selected Proﬁlin-1 as a test case to
9%
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11%
7%
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24%
Function
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Calcium binding
Immune response
Unknown
Chromosome stability
Protein degradation
Cell structure
Transport
Figure 4: This ﬁgure represents the percentage of expressed
proteins according to their cellular function.
determineiftheresultsoftheproteomicanalysesarefeasible.
As illustrated in Figure 5, Proﬁlin-1 is present in both the
SKBR3 and the human salivary gland (HSG) epithelial cell
lines. Additionally, Proﬁlin-1 is present in saliva and is
downregulated to HER2-receptor-positive status. The pilot
evidence supports the proteomic prediction.
It is worth noting that among the list (Table 3)o fS K B R 3
cell lysates proteins, there is a distinct absence of any proteins
related to immune response to inﬂammatory cancer activity
as compared to the salivary proteins listed in both Tables 1
and2.Theﬁndingsatthispointsuggestthestrengthofthisin
vivo model which could be indicative of response to therapy
in the event these proteins are diminished in activity during
treatment, thereby, indicating a response to therapy.
Further research is required to support the theories
presented in this paper. For example, proteomic analyses
of low-abundance proteins in the SKRB3 cell line lysates
and saliva are required in order to address gaps in varying
molecular pathways. Studies validating the panel of markers
are also necessary, and an assessment of salivary protein
modulation during trastuzumab therapy is essential.
5. Conclusions
The results of the study suggest salivary protein alterations
secondary to HER2 receptor status. This is not surprising
consideringthattheductalcellsofthesalivaryglandscontain8 Journal of Oncology
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Figure 5: It illustrates the presence of proﬁlin-1 in the SKBR3 and HSG cell lysates and saliva sampled from healthy, benign, and malignant
tumor patients. Proﬁlin is a downregulated protein in the presence of malignancy, and it is visualized by the lighter bands associated with
malignancy. It is also worth noting that the Her2/neu-receptor-negative band is darker than the Her2/neu-receptor-positive counterpart
suggesting further downregulation of the proﬁling-1 protein.
HER2/neu receptors. More importantly, the study raises the
notion that salivary gland protein secretions may be used
as a “real-time”, in vivo model for studying breast cancer
progression[9,10].Currently,therearethreemajormethods
for creating models for studying breast cancer progression
[18]. The three methods utilize either breast cancer tumor
cell lines xenografts of cell lines, and the third method uses
animals—in this case genetically engineered mice [19]f o r
creating various models for studying breast cancer [18].
All three models have generated useful insight into cancer
progression; however, despite their utility, no individual
modelrecapitulatesallaspectsofcancerprogression[18,19].
Hence, an adjunct, in vivo model system is needed for
breast cancer tumorigenesis and predictive modeling for
treatment response [18, 19]. The authors have demonstrated
in previous studies that the salivary protein proﬁles are
altered in the presence of ductal carcinoma in situ and are
further altered in the presence of lymph node involvement
[9, 10]. The preliminary ﬁndings of this paper coupled with
previous studies do imply that this in vivo experimental
model system, which utilizes one of the most easily obtained
body ﬂuids for marker analysis, may ﬁll in the current gaps
inourunderstandingofbreastcancerpathogenesis,signaling
pathways, the eﬃcacy of varying chemotherapeutics, and
identifying novel therapies. Most importantly, this new
approach may shed new light on metastatic progression that
is the principle cause of patient mortality.
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